In order to investigate the antitumor effect ofrecombinant human interleukin-J.8 (IL-J.8) alone and in combination with natural human tumor necrosis factor-a (nHuTNF-a), we used female BDFI mice bearing Lewis lung carcinoma (3LL). IL-J.8 showed an antiproliferative effect against pulmonary metastatic tumors of 3LL in a dose-dependent manner. We observed 19.6±6.6, 18.6±5.3, 14.1±4.4 and 13.0±6.0 metastatic tumors at doses of 0.5, 1.0, 2.5 and 5.0/lg IL-J.8/mouse/day by daily intravenous administration (the number of metastatic tumors of the control group was 26.3 ± 8.2). Similar results were obtained by intraperitoneal administration, but in this case, mice showed a marked decrease of body weight. When IL-J.8 was administered in combination with nHuTNF-a, pulmonary metastatic tumors decreased much more than when IL-J.8 was administered alone. When the control group had 18.6 ± 12.7 metastatic tumors, the nHuTNF -a group had 12.3 ± 3.9 and the IL-J.8 group had 12.8 ± 8.0, the group which was administered both cytokines had a significantly decreased number of 5.6 ± 3.3 metastatic tumors. This antiproliferative effect of IL-J.8 in combination with nHuTNF-a was reduced by the intravenous administration of anti-asialo GM 1 antibody and carrageenan. The number of metastatic tumors was increased from 8.9±8.0 to 18.8±11.4 by anti-asialo GM 1 antibody and from 9.5 ± 6.8 to 28.0 ± 12.3 by carrageenan. It was suggested that asialo GM1-positive cells and macrophage were two of the most important effectors of the antiproliferative effect of IL-J.8 and TNF-a.
Interleukin-l (IL-l) is a cytokine, which is produced by various cells including macrophages. It has a number of biological activities which are relevant in various ways to immunological, infectious and inflammatory stimuli.·) Recently, Kikumoto et a1.2) accomplished the purification and characterization of recombinant human IL-l,8 pro-. duced in Escherichia coli. and its mUltiple biological activities can now be investigated by utilizing highly purified recombinant IL-l preparations.
Though IL-l and tumor necrosis factor (TNF) do not bind to the same receptor, they have a number of similar biological activities: they induce endothelial tissue factor, suppress lipoprotein lipase activity,l) stimulate collagenase and prostaglandin synthesis,4) increase expression of HLA-A, B antigens,'·6) induce fever,') activate neutrophils, 8.9 ) and promote growth of fibroblasts. Concerning the cytotoxicity of TNF-a and IL-l in vitro. Ruggiero and Baglioni lO ) and Last-Barney et a1. 4) reported that TNF-a and IL-l exhibit synergistic action in cytotoxicity assays on human melanoma and carcinoma cell lines.
This study was undertaken to examine the combined nHuTNF-a-and IL-l,8-mediated antiproliferative effect on pulmonary metastatic tumors of Lewis lung carcinoma (3LL). The purpose was to gain some insight into the mechanism of action of these cytokines. Our results showed that low concentrations of IL-l,8 and nHuTNFa, administered together, synergistically inhibit the pro-1026 liferation of metastatic tumors of 3LL. In addition, on some schedules of administration around the time of operation (amputation of tumor-bearing leg), IL-l, 8 showed contradictory effects against the lung metastasis of 3LL. We wanted to examine the possible usefulness of IL-l,8 in combination with nHuTNF-a to see whether such a combination is favorable or not in respect to antitumor effect. It was found in murine syngenic tumor (3LL) models that nHuTNF-a significantly augmented the antitumor effect of IL-l,8.
MATERIALS AND METHODS
Animals Specific-pathogen-free female BD (C57BL/6 X DBA/2)F. mice, aged 7 weeks, were purchased from Shizuoka Laboratory Animal Center, Shizuoka. They were housed in a conventional environment and fed with normal mouse pellets and tap water ad libitum during the experiments. Eight-week-old mice were used for tumor inoculation. Tumor 3LL cells were serially passaged subcutaneously in C57BL/6 mice at the First Department of Surgery, Okayama University Medical School. For the experiment, tumors were excised aseptically on the 10th day after the last transplantation, minced, washed three times with Hanks solution, treated with 0.25% trypsin (Difco Labs, Detroit, MI) at 37°C for 15 min, washed twice with Eagle's minimal essential medium (MEM, GIBCO Labs, Grand Island, NY) supplemented with 10% fetal calf serum (GIBCO Labs), filtered twice through #lS0 wire mesh and prepared as a single cell suspension (4 X 10' cells/ml). The viability of the cells was over 9S%. Reagents Recombinant human interleukin-1,8 (IL-1,8)2) was supplied by Otsuka Pharmaceutical Co. Ltd., Tokushima (LAF activity: 2X 10' units/mg protein). Natural human TNF-a was purified from human acute B lymphoblastic leukemia cells (BALL-l cells) stimulated by HVJ and was supplied by Hayashibara Biochemical Laboratories, Inc., Okayama.
11 ) Its specific activity was 7 X 10 8 U/mg protein (2 X 10 6 JRU). The cytotoxicity of this preparation was determined by means of the highly sensitive and rapid assay of Eifel et al. for lymphotoxin, using actinomycin D-treated mouse L929 cells as the target. One unit of activity is designated as the reciprocal of the dilution that has a cytopathic effect in SO% of the target cells. Lyophilized anti-asialo GMI antiserum (Wako Pure Chemical Industries, Ltd., Osaka) was reconstituted with saline prior to use. As reported previously, anti-asialo GM I antibody can completely eliminate natural killer activity in vitro when diluted in the presence of guinea pig complement (1:10).12.13) For the in vivo experiments, SOO fJ,g of anti-asialo GM I antibody was administered into the tail vein of mice just before the first injection of IL-1,8 and nHuTNF-a. Lambda carrageenan (CRG) (Sigma Chemical Co., St. Louis, MO), which is toxic to macrophages,14. IS) was suspended in saline prior to use at a concentration of S mg/ml and sterilized by autoclaving at 120°C for 15 min. CRG solution (0.2 ml) was injected slowly into a lateral tail vein on the day before amputation (day -1) of the tumor-bearing leg. Spontaneous pulmonary metastasis model 3LL cells (1 X 10 6 /0.025 ml) were inoculated into the left footpad of BDFI mice, and the tumors which formed were regarded as the primary tumors. They were removed by femoral amputation under ether anesthesia on the 10th day (day 0) after the inoculation. On day 11, the mice were killed with ether and weighed. After that, the metastatic pulmonary tumors were counted by Wexler'S method. 16 ) In brief, their lungs were excised in one piece, dyed with Indian ink, washed for 5 min with tap water, bleached and fixed in Fekete's solution for 24 h, then the metastatic tumors were counted with the naked eye. The mean values and standard deviation (SD) of each group were caluculated. Statistical analysis was carried out by the use of Student's t test.
RESULTS
Antiproliferative effect of IL-lfJ on metastatic pulmonary tumors of 3LL in BDF) mice Table I (Fig. 1). ,..., .,
...... In experiment I, IL-I;9 and nHuTNF-a were administered into the tail vein of 7 mice in each group at the indicated dose daily for 10 days. In experiment 2, IL-I;9 was injected into the tail vein of 9 mice on days 1, 2, S, 6, in order to administer the same total dose as in experiment 1. nHuTNF-a was injected in the same way as in experiment 1. Saline (0.1 ml!mouse/day) was injected into the tail vein of 7 mice from each group, daily for 10 days as a control group. a) Anti-asialo GM! antibody (500 ,ug/mouse) was given intravenously on day I, before the first administration of IL-I;9 and nHuTNF-;9. IL-1;9 and nHuTNF-a were administered into the tail vein of 8 mice in each group at doses of 1.0,ug/mouse/ day and IOZ V/kg/day daily for 10 days. Saline (0.1 ml!mouse/ day) was injected as a control. Carrageenan (1 mg/mouse) was given intravenously on day -1. The doses of 1.0 ,ug/mouse/day of IL-1;9 and lOZ V/kg/ day of nHuTNF-a were administered into the tail vein of 6 mice in groups I and 3, and S mice in groups 2 and 4 daily for 10 days. Saline (0.1 ml!mouse/day) was injected as a control. Antiproliferative effect of IL-l,B combined with nHu-TNF-a on metastatic pulmonary tumors of 3LL in BDFI mice 8 was administered at doses of 1.0 and 2.5 .ug/mouse/day, and nHuTNF-a was administered at the dose of 10 2 V/kg/day, from day 1 to day 10. 17 ) These doses of each reagent separately did not decrease the numbers of metastatic pulmonary tumors significantly, and did not decrease the weight of the mice. The combined anti proliferative effects of these reagents against metastatic tumors are shown in Table II . When the number of the metastatic tumors of the control group was 18.6± 12.7, the group injected with nHuTNF-a alone had 12.3±3.9 metastatic tumors, and the group which was injected with IL-l,8 (1.0 ,Ltg/mouse/day) alone had 12.8 ± 8.0 metastatic tumors. The group which was injected with both cytokines simultaneously had a significantly (P<O.OS) decreased number of S.6±3.3 metastatic tumors compared with each group injected with a single cytokine. A similar result was obtained when we used a dose of 2.S ,Ltg/mouse/day of IL-l,8 and a dose of 10 2 U/kg/day of nHuTNF-a. Antiproliferative effect of IL-1,8 combined with nHu-TNF-a on 3LL in anti-asialo GMt antibody-pretreated mice As shown in Table III , the number of metastatic tumors of group 3 (IL-l,8+nHuTNF-a) was 8.9±8.0, which was a considerable reduction compared with group 1 (control group). Treatment with anti-asialo GMI antibody on day 1 (group 2) increased the number of metastatic tumors (36.8± 19.5) . Group 4 (treated with antiasialo GM I antibody just before the first injection, of both cytokines) showed 18.8 ± 11.4 metastatic tumors. This differs from group 3 (P< O.OS). No significant variation in murine body weight was recognized. Antiproliferative effect of IL-1,8 combined with nHu-TNF-a on 3LL in carrageenan-pretreated mice As shown in Table IV , the number of metastatic tumors of group 3 (lL-I,8+nHuTNF-a) was 9.S±6.8, which was a considerable reduction compared with group 1 (control group). Group 2 (treated with CRG on day -1) had an increased number of metastatic tumors (43.2± IS. 1). Group 4 (treated with CRG before the injection of both cytokines) showed 28.0± 12.8 metastatic tumors. This differed from group 3 (P<O.OS).
DISCUSSION
The antitumor effects of IL-1 are both direct and indirect. The latter effect arises from actions on the immunosystem and the inflammatory system; It has been reported that IL-1 has a direct antiproliferative effect against several human carcinoma cell lines, which derives from the reduction of ornithine decarboxylase activity. 18) There are reports of antitumor effects in vivo, such as an antiproliferative effect and a survival-enhancing effect, using Meth A sarcoma, sarcoma 180, XSS63 myeloma, MH134 hepatoma, Lewis lung carcinoma and L1210 lymphoma. Ebina and Ishikawa l9 ) observed an antimetastatic effect of IL-1,8 in the double grafted tumor system of Meth-A when IL-l,8 was injected intratumorally. Nakamura et al. 20 ) reported that IL-Ia showed a strong antitumor effect against Meth A sarcoma, B16 melanoma, Colon 26 adenocarcinoma and Lewis lung carcinoma in vivo.
This report presents data concerning the antiproliferative effects of IL-I,8 alone and in combination with nHuTNF-a against 3LL on BDFI mice. We know of no To determine whether the antiproliferative activity of IL-1,8 was truly synergistic with that of nHuTNF-a, the data were plotted in an isobologram. The concentrations of these cytokines which individually or in combination decreased the number of the metastatic tumors by SO%, are plotted in Fig. 2 . In this graphic analysis, a marked departure of the line connecting the experimental points below the diagonal is indicative of a synergistic interaction. The results of this analysis indicated that IL-I,8 and nHuTNF-a decreased the number of metatastic tumors in a truly synergistic way, and suggested that these cytokines activated different antiproliferative mechanisms.
This antiproliferative effect of IL-l,8 and nHuTNF-a was reduced by the intravenous administration of antiasialo GM I antibody and carrageenan. Thus it was suggested that asialo GMI-positive cells, including natural killer cells, and macrophages are important effectors of the antiproliferative activities of IL-l,8 and nHuTNFa. Concerning the antitumor effect of asialo GMI-positive cells, Nishiyama et al. 21 ) reported, using the colon 26 hepatic metastasis model, that histological examination of liver specimens in mice pretreated with nHuTNF-a . revealed considerable lymphocytic infiltration around the tumor nodules, and that most of the lymphocytes proved to be asialo GMI-positive.
Several reports have suggested possible mechanisms of the antitumor effect of IL-l and TNF-a. Lowenthal et al. 22 ) showed that recombinant IL-l can induce both the secretion of IL-2 and the expression of IL-2 receptors by EL4 thymoma cells. Eisenthal and Rosenberg23) suggested that lymphokines such as IL-l and TNF may synergize with IL-2 in the induction of antibodydependent cellular cytotoxicity and could thus potentially be useful for immunotherapy of established tumors when combined with the administration of specific antitumor antibodies. Myers et al.24 ) demonstrated that mRNA expression and production of both TNF-a and IL-l,8 in bone marrow-derived macrophages correspond to the stage of differentiation at which the cells acquire tumoricidal and antigen presentation activities. Ichinose et al. H ) suggested that IL-l and TNF are major cytotoxic molecules for activation of monocyte-macrophagemediated tumor lysis. In addition, Sayers et al. 26 ) reported that the synergy of IL-l and TNF in promoting polymorphonuclear neutrophil influx into the injected sites suggested that the local production of very low concentrations of these cytokines in situ could play a critical role in the emigration of PMN. IL-l and TNF augment neutrophil chemotaxis through the induction of monocyte-derived neutrophil chemotactic factor.
)
These reports suggest that IL-l might show an antitumor effect through neutrophil activation. There have been few reports on the cytocidal or cytostatic activity of neutrophils, so we should investigate the cytotoxic activity of neutrophils as well as other effectors on tumor cells. We also got contradictory results when IL-l,8 was administered at different times (data not shown). These data revealed that when mice were injected with IL-l,8 in the preoperative period and postoperative period, there was an antitumor effect. But perioperative injections of IL-l,8 tended to have a proliferative rather than an anti proliferative effect. A similar phenomenon was found with nHuTNF-a by Nishiyama et al. 21 ) in the colon 26 hepatic metastasis model. These results may suggest the difficulty of the clinical use of these cytokines as adjuvant immunotherapy for cancer therapy. But considering that the preoperative injections of IL-l,8 showed an antitumor effect, IL-l,8 may have an antimetastatic effect. Our next study will be designed to investigate the mechanism of the antimetastatic effect of IL-l,8 and to determine whether it really has a strong antimetastatic effect or not, because metastasis is a major problem in cancer therapy.
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